Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by drjekylon Jul 11, 2017 10:16am
128 Views
Post# 26454933

RE:RE:RE:General meeting Sep 5th

RE:RE:RE:General meeting Sep 5thagms are required so that management can get approval from the shareholders. most agms are the same from company to company whereby the seek approval for the board of directors, the auditor, the stock option plan, sometimes a consolidation, sometimes to issue more than 50% of the outstanding equity and any other business that may come before the meeting.
typically the meetings are approved as presented by the chariman because no one ever shows up.
i don't suspect a bombshell's worth of news at this agm unless you consider the aforementioned list noteworthy of a bombshell.
for the record, directors don't drive equity values higher for biotechs. successful work programs drive equity values higher!

drj!
Bullboard Posts